Altor currently has two products in clinical development. Our lead product ALT-801, a T-cell receptor-targeted immunotherapeutic developed from the STAR™ platform technology for cancer, concluded a Phase I/IIa clinical trial in patients with metastatic malignancies in 2009 (Fishman, et al. 2011 Clin Cancer Res 17:7765 - Pubmed Link) and a Phase II trial for ALT-801 in combination with cisplatin for patients with metastatic melanoma in 2Q-2012. A second Phase II trial for ALT-801 in combination with gemcitabine and cisplatin is enrolling patients with locally advanced or metastatic urothelial carcinomas of the bladder, ureter, urethra and renal pelvis. A third Phase II trial is underway for ALT-801 in combination with gemcitabine for patients with non-muscle invasive bladder cancer who have failed BCG treatment. A fourth Phase II trial for ALT-801 is also enrolling patients with refractory multiple myeloma. ALT-801 is also being evaluated in a trial in combination with donor lymphocyte infusion in patients with acute myeloid leukemia. (More on ALT-801 - PDF...)
Our second product ALT-836, a monoclonal antibody-based tissue factor antagonist, completed a second 90-patient, multi-center, randomized, placebo-controlled, Phase II trial for treatment of patients with Acute Respiratory Distress Syndrome and Acute Lung Injury, a life-threatening, systemic inflammatory disease. A dose-escalating Phase I/IIa clinical trial for ALT-836 in combination with gemcitabine has been completed for treatment of patients with solid tumors who failed the standard-of-care treatments. (More on the Clinical Trials...)
Numerous product candidates that have completed proof-of-principle studies in animal models are in pre-clinical development for treatment of cancer, infectious, inflammatory and autoimmune diseases.